HDAC9 and acute myeloid leukemia: To improve the anti-leukemic effects, one might also consider combinations of (derivates of) the lead structures with traditional chemotherapeutic agents such as cytarabine or daunorubicin, or with inhibitors that target transcription factors, such as AP-1, or epigenetic regulators, such as DNA methyltransferase or HDAC inhibitors, which might provide synergistic effects for treating acute myeloid leukemia.